A Phase 3 interventional study of Odevixibat and Placebo in Biliary Atresia, sponsored by Albireo, an Ipsen Company. Completed at 72 sites in 19 countries. Open to participants aged Up to 111 Days. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Albireo, an Ipsen Company (part of Ipsen) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Biliary Atresia with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Biliary Atresia · United States.
Among the 22 studies in Biliary Atresia with a site in United States, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 3, and was the 16th registered.
78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.
Browse Biliary Atresia studies →8 of the 22 studies in Biliary Atresia with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 2 wk–4 mo · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0 days–3 mo
Holterman, Ai-Xuan, M.D. · Sites in United States, Pakistan, Vietnam
Ages 14 days–180 days
University of Pittsburgh · Sites in United States
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.
This study: Up to 111 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 3
First in 2000; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 254 is above the median of 45 across 43 interventional studies indexed under Biliary Atresia.
Median enrollment 53 across the 14 interventional studies, 776 across the 8 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Albireo, an Ipsen Company, one of the names counted as Ipsen. Under that name alone:
Albireo, an Ipsen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.
Ipsen has 2 studies filed under Biliary Atresia — fewer than ten, so there is no comparison to draw.
1 of the studies in Biliary Atresia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07250854University of Alabama at BirminghamThe Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Biliary Atresia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
Up to 70 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsules for oral administration once daily for 104 weeks.
Drug: Odevixibat
Capsules for oral administration (to match active) once daily for 104 weeks.
Drug: Placebo
Odevixibat is a small molecule and selective inhibitor of IBAT.
Placebo identical in appearance to experimental drug (odevixibat).
Time from randomization to first occurrence of liver transplant, or death
Time frame: From baseline to Week 104
Proportion of patients with liver transplant
Proportion of patients who are alive and have not undergone a liver transplant
Time frame: From baseline to Week 104
Time to onset of any sentinel events
Time to onset of any sentinel events
Time frame: From baseline to Week 104
Total bilirubin levels
Total bilirubin level after 13, 26, 52, and 104 weeks of study treatment
Time frame: From baseline to Weeks 13, 26, 52 and 104
Serum bile acid levels
Serum bile acid level after 13, 26, 52, and 104 weeks of study treatment
Time frame: From baseline to Weeks 13, 26, 52 and 104
Time to pediatric end-stage liver disease (PELD) score >15
Time to pediatric end-stage liver disease (PELD) score \>15
Time frame: From baseline to Week 104
Percentage of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From baseline to Week 104
Percentage of participants with clinically significant changes in Physical Examination
Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be graded by the investigator.
Time frame: From baseline to Week 104
Percentage of participants with clinically significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)
Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator.
Time frame: From baseline to Week 104
Percentage of participants with clinically significant changes in Abdominal Ultrasound findings
Percentage of participants with clinically significant change in Abdominal Ultrasound findings will be reported. The clinical significance will be decided by the investigator.
Time frame: From baseline to Week 26 and Week 104
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Ran from Jul 2020 to primary completion in Jun 2026, 71 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Odevixibat